On November 22, 2024, PAVmed Inc. completed the sale of $21.95 million in principal amount of Lucid Diagnostics Inc.’s Senior Secured Convertible Notes, known as the “Lucid 2024 Convertible Notes,” in ...
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
For patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and then surgery is promising.